Phase 3, 28-week, Randomized, Double-blind, Placebo-controlled Safety and Efficacy Study of Nabiximols as an add-on Therapy in Subjects With Spasticity Due to Multiple Sclerosis.

• Status: Withdrawn
• Trial end date: 1969-12-31

Summary

The purpose of this study is to determine the effective dose range and to demonstrate a non-effective dose range of Sativex compared with placebo in relieving symptoms of spasticity due to multiple sclerosis.

• Phase: Phase 3

Details

• Lead Sponsor: GW Research Ltd
• Treatments: Dronabinol; Ethanol; Nabiximols; Peppermint oil